Brief: Organon Enters Into Agreement To License Miudella®
23/02/2026 12:36
Feb 23 (Reuters) - Organon & Co OGN.N: ORGANON ENTERS INTO AGREEMENT TO LICENSE MIUDELLA®, SEBELA PHARMACEUTICALS’ HORMONE-FREE INTRAUTERINE DEVICE ORGANON & CO - CO TO PAY $27.5 MILLION WITH UP TO $505 MILLION IN MILESTONES Source text: ID:nBw1jwhtQa Further company coverage: OGN.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Organon & Co.
See all newsIndia's Sun Pharma misses debt fundraise goal as investors demand higher yields, bankers say
Brief: Organon & Co Says It Does Not Expect To Record Milestone Expense In Q3 2026
India's Persistent Systems plans debut rupee debt sale to fund acquisition, bankers say
India's Sun Pharma plans $1 billion local debt sale for loan takeout, sources say
Organon & Co reports results for the quarter ended June 30 - Earnings Summary